Reconsideration of the use of meningococcal polysaccharide vaccine.

Reconsideration of the use of meningococcal polysaccharide vaccine.

In 2005, a quadrivalent meningococcal conjugate vaccine was licensed in the United States for persons aged 11-55 years of age. For children aged 2-10 years with underlying diseases associated with increased risk of meningococcal disease, unconjugated meningococcal polysaccharide (MPS) vaccination is...

Descripció completa

Dades bibliogràfiques
Autors principals:	Granoff, D, Pollard, A
Format:	Journal article
Idioma:	English
Publicat:	2007

Ítems similars

Meningococcal polysaccharide-protein conjugate vaccines.
per: Snape, MD, et al.
Publicat: (2005)

Meningococcal A, C, Y and W-135 polysaccharide-protein conjugate vaccines.
per: Pace, D, et al.
Publicat: (2007)

Meningococcal polysaccharide-protein conjugate vaccines (vol 5, pg 21, 2005)
per: Snape, MD, et al.
Publicat: (2005)

Mutant Native Outer Membrane Vesicles Combined with a Serogroup A Polysaccharide Conjugate Vaccine for Prevention of Meningococcal Epidemics in Africa.
per: Rolando Pajon, et al.
Publicat: (2013-01-01)

Meningococcal vaccines.
per: Bethell, D, et al.
Publicat: (2002)

Meningococcal disease. Meningococcal conjugate polysaccharide vaccines and new generation vaccines. Report 3
per: M. V. Abramtseva, et al.
Publicat: (2018-02-01)

Meningococcal vaccines.
per: Rüggeberg, J, et al.
Publicat: (2004)

Meningococcal vaccines.
per: Collins, C, et al.
Publicat: (2002)

Meningococcal vaccine. From capsular polysaccharides of microbes to proteases
per: A P Alliluyev, et al.
Publicat: (2012-12-01)

Meningococcal disease. Polysaccharide meningococcal vaccines. The historical aspects and the current state of vaccine development. Report 2
per: M. V. Abramtseva, et al.
Publicat: (2018-02-01)

Erratum: Meningococcal polysaccharide-protein conjugate vaccines (Lancet Infective Diseases (2005) 5 (21-30)
per: Snape, MD, et al.
Publicat: (2005)

B cell responses to conjugate and polysaccharide meningococcal vaccines
per: Ramasamy, M
Publicat: (2012)

High-dimensional assessment of B-cell responses to quadrivalent meningococcal conjugate and plain polysaccharide vaccine.
per: O'Connor, D, et al.
Publicat: (2017)

Quadrivalent meningococcal conjugate vaccines
per: Pace, D, et al.
Publicat: (2009)

Quadrivalent meningococcal conjugate vaccines.
per: Pace, D, et al.
Publicat: (2009)

Vaccines for prevention of meningococcal disease.
per: Pollard, A, et al.
Publicat: (2000)

Meningococcal disease and vaccination in North America.
per: Pollard, A, et al.
Publicat: (2001)

Further Insights into the Measurement of Free Polysaccharide in Meningococcal Conjugate Vaccines
per: Nicola J. Beresford, et al.
Publicat: (2025-02-01)

The epidemiology of meningococcal disease and the impact of vaccines.
per: Khatami, A, et al.
Publicat: (2010)

Baseline polysaccharide-specific antibodies may not consistently inhibit booster antibody responses in infants to a serogroup C meningococcal protein-polysaccharide conjugate vaccine
per: Blanchard-Rohner, G, et al.
Publicat: (2012)

Baseline polysaccharide-specific antibodies may not consistently inhibit booster antibody responses in infants to a serogroup C meningococcal protein-polysaccharide conjugate vaccine.
per: Blanchard-Rohner, G, et al.
Publicat: (2012)

Global epidemiology of meningococcal disease and vaccine efficacy
per: Pollard, A
Publicat: (2004)

Global epidemiology of meningococcal disease and vaccine efficacy.
per: Pollard, A
Publicat: (2004)

Group B meningococcal vaccine: Recommendations for UK use
per: Pollard, A, et al.
Publicat: (2014)

Group B meningococcal vaccine: recommendations for UK use.
per: Pollard, A, et al.
Publicat: (2014)

Vaccine prevention of meningococcal disease, coming soon?
per: Morley, S, et al.
Publicat: (2001)

Vaccine prevention of meningococcal disease, coming soon?
per: Morley, S, et al.
Publicat: (2001)

Safety and immunogenicity of quadrivalent meningococcal polysaccharide vaccine (MPV ACYW135) compared with quadrivalent meningococcal conjugate vaccine (Menactra®) in Malian children
per: Samba O. Sow, et al.
Publicat: (2023-08-01)

Safety and Immunogenicity of a Tetravalent Polysaccharide Vaccine Against Meningococcal Disease
per: Pei-Lan Shao, et al.
Publicat: (2009-07-01)

Effectiveness analyses may underestimate protection of infants after group C meningococcal immunization
per: Vu, D, et al.
Publicat: (2006)

Randomized clinical trial to evaluate the immunogenicity of quadrivalent meningococcal conjugate and polysaccharide vaccines in adults in the United kingdom.
per: Ramasamy, M, et al.
Publicat: (2014)

Effectiveness analyses may underestimate protection of infants after group C meningococcal immunization.
per: Vu, D, et al.
Publicat: (2006)

Plasma cell antibody repertoire analysis following administration of meningococcal polysaccharide and protein-polysaccharide conjugate vaccines: evidence of distinct patterns of B cell activation
per: Galson, J, et al.
Publicat: (2014)

The next chapter for group B meningococcal vaccines
per: Wang, N, et al.
Publicat: (2017)

Group B meningococcal vaccine science and policy
per: Drysdale, SB, et al.
Publicat: (2015)

Serogroup B meningococcal vaccines-an unfinished story.
per: Sadarangani, M, et al.
Publicat: (2010)

Meningococcal meningitis in sub-Saharan Africa: the case for mass and routine vaccination with available polysaccharide vaccines
per: Robbins John B., et al.
Publicat: (2003-01-01)

Meningococcal factor H binding proteins in epidemic strains from Africa: implications for vaccine development.
per: Rolando Pajon, et al.
Publicat: (2011-09-01)

The development and certification of the industrial reference standard for identification of meningococcal polysaccharide vaccine group A
per: M. V. Abramtseva, et al.
Publicat: (2018-02-01)

MEMORY B CELL RESPONSES FOLLOWING IMMUNISATION WITH POLYSACCHARIDE AND CONJUGATE QUADRIVALENT MENINGOCOCCAL ACYW135 VACCINES IN HEALTHY ADULT VOLUNTEERS
per: Maheshi, R, et al.
Publicat: (2010)